Drug market imbalance is bad for patient health, and counter-intuitive to modern health needs. We seek to redress this imbalance specifically in the rare disease space.


James Harrison


James Harrison was formerly CEO of Archimica, an international contract manufacturing organisation of active pharmaceutical ingredients and their pre-cursors for the global branded and generic pharmaceutical industries.

Archimica has manufacturing sites in the US, UK, Germany, France and Italy.  During his tenure at Archimica, James recruited and led a new management team, and implemented a detailed strategic repositioning of the business. Archimica was sold to the Euticals group in 2011.

Prior to Archimica, James was a Managing Director at TowerBrook Capital Partners and a Partner at Soros Private Equity Partners. James began his career working in the mergers and acquisitions department of Morgan Stanley.

Bill Robinson


Mr Robinson was formerly COO of UCB, a Brussels-based global biopharmaceutical company, where as a member of the Executive Committee, he was responsible for their global commercial operations.  Previously, Mr Robinson had worked for over 35 years for Eli Lilly, one of the leading US pharmaceutical companies, where he held a number of senior international management roles in Sales and Marketing, General Management, and Research and Development. Prior to his retiring from Lilly he was VP for US Sales and Marketing.

Bill is a former Chairman of Plethora Solutions an AIM-listed UK pharmaceutical company, and a former Board Director of Sciele Pharma, which was a NASDAQ listed company prior to its acquisition by Shionogi.

Antonio Benedetti


Antonio Benedetti was formerly the CEO of Magirus, one of the world largest Fire Engines company.

Since 1864, Magirus has stood for innovation and tradition for firefighters around the world. Providing comprehensive state-of-the-art fire trucks, ladders, rescue and equipment vehicles as well as special solutions, pumps and portable pumps, Magirus is one of the largest technology leaders in the firefighting industry. With more than 1.300 employees and operations in Germany, Austria, Italy and France, Magirus is present in more than 100 countries and in the last few years has been through an intensive turnaround which involved footprint, operations, product portfolio renewal, global expansion and Brand repositioning.

Prior to Magirus, Mr Benedetti was Group CFO and Director of Archimica, an international contract manufacturing organisation of active pharmaceutical ingredients and their pre-cursors for the global branded and generic pharmaceutical industries.

Prior to Archimica, Mr Benedetti worked for more than 10 years in different sectors of the Fiat Group, including Case New Holland, Fiat Powertrain Technologies and Fiat Group Automobiles.

Duncan Moore


Dr Moore was previously the Global Head of Healthcare Research at Morgan Stanley.

He is Chairman of Lamellar Biomedical, Chairman of Oncology Venture and Chairman of StepJockey. Dr Moore is also a Board Director of Forward Pharma, the NASDAQ listed biotechnology company and he is a partner in East West Capital Partners.

Allen Lefkowitz


Mr Lefkowitz has nearly 25 years of experience in the generic pharmaceutical industry.

Mr Lefkowitz is a Managing Director at Torreya Partners.

Previously, Mr Lefkowitz worked for 19 years at Teva Pharmaceuticals, where he was the Chief Financial Officer for the Commercial Operations of the API division. Following this Mr Lefkowitz moved to Sandoz, the generic subsidiary of Novartis pharmaceuticals, as Vice President of Business Development and Licensing.

Ross Reason


Mr Reason, a fellow of Robinson College, University of Cambridge is an economist, accountant and former head of trading at an investment bank.

Mr Reason is currently on the board of a number of companies including Cambridge University Investment Management Ltd, HgCapital LLP and ED&F Man, amongst others.


Our Management Team


Why Cycle Pharma


Want to know more about Cycle?

Contact us today